The funds will help support the firm's clinical development of a blood-based transcriptomic assay for the screening and detection of breast cancer.
The work aboard the International Space Station may help researchers better understand how conditions in space affect DNA damage and repair pathways.
Started by the entrepreneur behind the Teladoc telemedicine platform, Recuro Health sees genomics as the "foundation" of a more effective healthcare system.
GTC will use its Solid Tumor Profile Plus test to identify solid cancer patients with NRG1 gene fusions for enrollment in Elevation's Phase II CRESTONE trial.
The Guardian reports that a researcher resigned as editor-in-chief of a journal after it declined to publish his article urging academic journals to take a stance on human rights violations in China.
In Genome Research this week: analysis of Neisseria meningitidis recombination, protein-truncating variants affecting psoriasis, and more.
Twist said the acquisition will enhance its abilities to support multiplex sequencing preparations across multiple markets.
The agreement connects SpeeDx chemistry with MolGen's equipment for a fully integrated, high-throughput sample-to-answer workflow, the firms said.
Qiagen will globally distribute Verogen's human ID products, and the companies will combine Verogen’s NGS workflows with Qiagen’s sample prep automation.
CareDx has appointed Hannah Valantine to its board of directors.
Valantine is a professor of medicine at Stanford and the former NIH CSO for Scientific Workforce Diversity. Prior to joining the NIH, she served as professor of cardiovascular medicine and senior associate dean for diversity and leadership at Stanford. Valantine has partnered with CareDx for several years, including as a principal investigator on publications for the company's AlloMap Heart test, and is one of the researchers behind the original patents for CareDx's AlloSure test.
The Japanese MHLW approved the real-time PCR-based test as a CDx to detect four driver genes for nine associated NSCLC targeted therapies.
The Pleasanton, California-based company has developed super-resolution optical technology for use in sequencing and single-molecule protein detection.
Progenity has appointed Surbhi Sarna to its board of directors effective July 1. She is currently a visiting partner at Y Combinator. Sarna founded nVision Medical and acted as CEO of the medical device company until it was acquired by Boston Scientific in 2018, where she led commercial efforts for nVision until 2020. She previously served in healthcare engineering roles at BioCardia and Abbott Vascular.
Sarna is a board member at medical device company Penumbra and on its audit and nominating and corporate governance committees. She's also on the board of trustees at Astia, which provides access to capital and networks to women entrepreneurs.
BioSkryb, a Durham, North Carolina-based developer of genomic amplification technologies, has appointed Gary Harton as CSO. Harton has more than 30 years of experience in single-cell diagnostic product development, and will apply BioSkryb’s platform technology to develop new diagnostic technologies for cancer, neurological disorders, and assisted reproductive technologies, the company said. Prior to BioSkryb, he was the portfolio director for preimplantation genetic testing at PerkinElmer. He has also previously held a variety of product and portfolio-development positions at PerkinElmer, Igenomix US, Progyny, Illumina, BlueGnome, and Reprogenetics.
Synthetic biology and CRISPR have enabled researchers to develop wearable sensors that can detect a variety of viruses and bacteria, including SARS-CoV-2.
David Eustace has been appointed as operations director of cancer liquid biopsy startup Dxcover (previously ClinSpec Dx). He joins the Strathclyde University spinout from Bruker Daltonics, where he was operations director in Germany and Scotland. Previously, he worked for Renishaw Diagnostics. Eustace holds a PhD from the University of Glasgow.
A 5,000-year-old Y. pestis genome from a hunter-gatherer in present-day Latvia did not contain a virulence factor previously linked to plague transmission by flea vectors.
A significant subset of African Americans may be genetically predisposed to low white blood cell counts, suggesting this feature alone may not warrant bone marrow biopsies.